Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors - Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors

Influenza vaccination in the 23 patients included in the immunogenicity analyses significantly increased geometric mean titer for all strains, and seroprotection rate, seroresponse rate, and seroconversion rate were 52% to 91%, 26% to 39%, and 26% to 35%, respectively. In the 24 patients included in the safety analyses, 7 (29%) and 5 (21%) patients exhibited systemic and local reactions, respectively. Only one patient (4%) (hypothyroidism, grade 2) showed post-vaccination immune-related adverse events.